An observational study in Covid19 and Metabolism, Inborn Errors, sponsored by University Hospital, Lille. Withdrawn at 1 site in France. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University Hospital, Lille · Observational
No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19.
This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation.
The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
Browse COVID-19 studies →University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
Counted across the registry records on this site, refreshed daily.
IMD patients followed in reference centers for IMD in France. children and adult patients with MHM who have been infected with COVID-19 (tested positive or considered positive for COVID-19). Asymptomatic MHM patients tested positive for COVID 19 (contact case, for example) will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient affected by an inherited metabolic disease
Frequency of MHM imbalance triggered by COVID-19
disease aggravation or metabolic decompensation, among MHM-infected patients with COVID-19.
Time frame: at 8 weeks
Number of COVID-19 patients in Gaucher's disease
Time frame: at 24 months
Number of COVID-19 patients in Urea Cycle Disorder
Time frame: at 24 months
Severity of COVID-19 infection
severity of COVID-19 infection as assessed by hospitalization; Intensive Care Unit, death
Time frame: at 24 months
Ran from Feb 2021 to primary completion in Feb 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.